Protocol summary

Study aim
Investigating the effectiveness of probiotics in the treatment of jaundice in newborns
Design
Randomized clinical trial without blinded strain on 100 newborns with jaundice under treatment, who are divided into two intervention and control groups, and they differ only in terms of receiving probiotic drops, and to control confounding variables, logistic regression modeling methods were used. is used
Settings and conduct
Jaundiced newborns admitted to Mufaid Children's Hospital
Participants/Inclusion and exclusion criteria
Exclusion criteria include; Birth weight less than two kilos, birth age less than 35 weeks, physiological jaundice and bilirubin less than 15.Bilirubin is above 25 and requires blood exchange and the presence of co-morbidities in the newborn, as well as the parents' lack of consent
Intervention groups
Accelerating the effect of probiotic drops in the treatment of neonatal jaundice
Main outcome variables
The result of the study is the acceleration of the recovery of neonatal jaundice and no harm has been observed in the treatment with probiotic drops

General information

Reason for update
Acronym
EPN
IRCT registration information
IRCT registration number: IRCT20231020059774N1
Registration date: 2023-12-05, 1402/09/14
Registration timing: registered_while_recruiting

Last update: 2023-12-05, 1402/09/14
Update count: 0
Registration date
2023-12-05, 1402/09/14
Registrant information
Name
Samereh Ghorbani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 912 495 6577
Email address
samikh1985@yahoo.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2023-11-22, 1402/09/01
Expected recruitment end date
2025-03-20, 1403/12/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigating the effectiveness of probiotics in the treatment of jaundice in term and near_term newborns
Public title
Investigating the effectiveness of probiotics in the newborns
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
A newborn with a birth weight of more than 2 kg Childbirth age greater than 37 weeks Non-physiological jaundice and bilirubin more than 15 A newborn with bilirubin less than 25 A newborn doesnot need blood transfusion A newborn without abnormalities and comorbidities Parental consent
Exclusion criteria:
A newborn less than 2 days old Childbirth age less than 35 weeks Pathological jaundice A newborn with bilirubin above 20 A newborn with malformations and other co-morbidities A newborn needs a blood transfusion
Age
From 2 days old to 28 days old
Gender
Both
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 100
Randomization (investigator's opinion)
Randomized
Randomization description
Due to the fact that with the simple randomization method, there was a possibility that the balance between the groups would not be established, the method of examining the random allocation plan will be block randomization (Permuted). (block randomization in such a way that 100 people (determined according to the sample size) Divide into 25 blocks by using blocks of 4 and then as concealment will be assigned to study groups. In this study, the main researchers and the patient's parents did not know about the randomization method and random block allocation by The epidemiologist will do the planning
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Shahid beheshti University of Medical Sciences
Street address
Shariati St., above Hosseinieh Irshad, Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Approval date
2023-10-01, 1402/07/09
Ethics committee reference number
IR.SBMU.MSP.REC.1402.372

Health conditions studied

1

Description of health condition studied
Jaundice in infants and acceleration of treatment
ICD-10 code
P59
ICD-10 code description
Neonatal jaundice from other and unspecified causes

Primary outcomes

1

Description
Rapid decrease in bilirubinا
Timepoint
The beginning of hospitalization and the course of treatment and the time of discharge
Method of measurement
Bilirubin level in blood test

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: 50 newborns with jaundice will be randomly given 5 drops of (Reuteflor ) probiotic daily and its effect on reducing the duration of hospitalization of infants compared to the control group will be investigated.
Category
Treatment - Drugs

2

Description
Control group: Randomly, 50 hospitalized newborns with jaundice in the control group will not be given probiotics and will only go through the course of treatment for jaundice in the hospital.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Mofid hospital
Full name of responsible person
Samereh Ghorbani
Street address
Shariati Street, above Hosseinieh Irshad, Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
+98 912 495 6577
Email
samikh1985@yahoo.com
Web page address
https://mch.sbmu.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Dr. Reza Saidi
Street address
Shariati Street. Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
+98 912 495 6577
Email
samikh1985@yahoo.cm
Web page address
https://mch.sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Samereh Ghorbani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Shariati Street. Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
009822227021
Email
samikh1985@yahoo.com
Web page address
https://mch.sbmu.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Samereh Ghorbani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Shariati Street. Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
009822227021
Email
samikh1985@yahoo.com
Web page address
https://mch.sbmu.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Samereh Ghorbani
Position
Resident
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Shariati Street. Mofid Children's Hospital
City
Tehran
Province
Tehran
Postal code
1546815514
Phone
009822227021
Email
samikh1985@yahoo.com
Web page address
https://mch.sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
No decision has been made to share the data
When the data will become available and for how long
The access period starts 6 months after the results are published
To whom data/document is available
Researchers working in academic and scientific institutions and people who are also engaged in industry
Under which criteria data/document could be used
It does not need to be analyzed further
From where data/document is obtainable
وب سایت
What processes are involved for a request to access data/document
Access period 6 months after publication
Comments
Loading...